Chemomab Therapeutics (NASDAQ:CMMB) Given New $7.00 Price Target at Maxim Group

Chemomab Therapeutics (NASDAQ:CMMB) had its price objective boosted by Maxim Group from $4.00 to $7.00 in a report issued on Thursday,Benzinga reports. Maxim Group currently has a buy rating on the stock.

Separately, Oppenheimer reissued an “outperform” rating and issued a $11.00 target price (down from $13.00) on shares of Chemomab Therapeutics in a report on Friday, November 15th.

Chemomab Therapeutics Stock Performance

NASDAQ:CMMB opened at $1.77 on Thursday. Chemomab Therapeutics has a 52 week low of $0.58 and a 52 week high of $2.55. The firm has a market cap of $25.42 million, a price-to-earnings ratio of -1.77 and a beta of 0.66. The firm’s 50-day simple moving average is $1.97 and its 200 day simple moving average is $1.70.

Hedge Funds Weigh In On Chemomab Therapeutics

Several hedge funds have recently bought and sold shares of CMMB. Sphera Funds Management LTD. bought a new position in Chemomab Therapeutics in the 3rd quarter valued at about $1,907,000. Virtu Financial LLC bought a new position in Chemomab Therapeutics in the 4th quarter valued at about $26,000. Finally, XTX Topco Ltd boosted its stake in shares of Chemomab Therapeutics by 63.8% in the 4th quarter. XTX Topco Ltd now owns 24,929 shares of the company’s stock valued at $45,000 after purchasing an additional 9,706 shares in the last quarter. 46.05% of the stock is owned by institutional investors.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).